Cambridge Investment Research Advisors Inc. Has $9.67 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cambridge Investment Research Advisors Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 3.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,467 shares of the biopharmaceutical company’s stock after acquiring an additional 5,519 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Gilead Sciences were worth $9,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Landmark Wealth Management LLC bought a new stake in Gilead Sciences during the first quarter valued at about $30,000. Joseph P. Lucia & Associates LLC bought a new stake in Gilead Sciences during the first quarter valued at about $25,000. TFO TDC LLC bought a new stake in Gilead Sciences during the first quarter valued at about $27,000. Cornerstone Advisory LLC bought a new stake in Gilead Sciences during the fourth quarter valued at about $34,000. Finally, Mystic Asset Management Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at about $33,000. 78.58% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.4 %

Shares of GILD opened at $63.77 on Friday. The stock has a market cap of $79.93 billion, a price-to-earnings ratio of 19.44, a P/E/G ratio of 0.62 and a beta of 0.31. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.30. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $74.12. The company has a 50-day moving average price of $63.22 and a two-hundred day moving average price of $62.02.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.07. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $5.88 billion. Gilead Sciences had a net margin of 15.03% and a return on equity of 42.92%. Equities analysts predict that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be issued a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.58%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 89.02%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GILD. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Monday, August 15th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $63.00 to $74.00 and gave the company an “equal weight” rating in a report on Tuesday, September 13th. BMO Capital Markets started coverage on shares of Gilead Sciences in a research note on Tuesday, June 7th. They issued a “hold” rating and a $63.00 target price for the company. Morgan Stanley increased their target price on shares of Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. Finally, Truist Financial increased their target price on shares of Gilead Sciences from $71.00 to $76.00 and gave the company a “hold” rating in a research note on Thursday, September 15th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $73.53.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.